Crossmark

Change Details: The original online version of this article was revised: In this article the author name ‘Larry D. Anderson, Jr’ has been published as ‘Larry Anderson’.

Change Date: 31 August 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41408-026-01605-9

Ethics

Competing interests: DKH receives research funding from Bristol Myers Squibb, Janssen, Kite Pharma, Karyopharm, and Adaptive Biotech, and reports consulting or advisory roles with Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm. DD reports consulting for Karyopharm and Caribou Biosciences. HM receives honoraria from Bristol Myers Squibb, Pfizer, Janssen, Amgen, Takeda, GSK, FORUS, and Sanofi, and research funding from Pfizer and Janssen. AA receives research funding from AbbVie, Regeneron Pharmaceuticals, K36-Therapeutics, Janssen, and Adaptive Biotech, and honoraria from Karyopharm, Bristol Myers Squibb, Janssen, Sanofi, and Pfizer. NA receives research funding from Kite/Gilead and Pfizer and has consulting or advisory roles with Bristol Myers Squibb, Kite/Gilead, Invivyd Bio, Legend Bio, Johnson & Johnson, Autolus, and ADC Therapeutics; founder of Cortex (non-profit) and board member of USMIRC. LA receives consulting fees and honoraria from Pfizer, Bristol Myers Squibb, BeiGene, Sanofi, Amgen, Karyopharm, Celgene, Prothena, Cellectar, Johnson & Johnson, GSK, and AbbVie, and research funding from Bristol Myers Squibb, BeiGene, Johnson & Johnson, GSK, and AbbVie. RB reports consulting for AbbVie, Adaptive Biotech, Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Poseida Therapeutics, Sanofi, and SparkCures, and receives research funding from AbbVie, Bristol Myers Squibb, Janssen, Novartis, Pack Health, Prothena, and Sanofi. MM is supported by the Advancing a Healthier Wisconsin CTSI KL2 award, receives institutional research funding from Sanofi, Bristol Myers Squibb, and Celgene, and reports consulting for Sanofi, Bristol Myers Squibb/Celgene, Pfizer, Janssen Scientific Affairs, Legend Biotech, and Adaptive Biotech. SS reports consulting for Janssen, Bristol Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, AbbVie, Regeneron, BiolineRx, and Genentech/Roche, and receives research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis, and Bristol Myers Squibb. KKP reports consulting for Bristol Myers Squibb, Janssen, Pfizer, Arcellx, and Karyopharm Therapeutics, research funding from Bristol Myers Squibb, Poseida Therapeutics, Takeda, Janssen, Cellectis, Nektar, AbbVie/Genentech, Precision Biosciences, and Allogene Therapeutics, and travel support from Bristol Myers Squibb. ASM reports consulting for Bristol Myers Squibb. MCP receives honoraria from Gilead and research funding from Kite/Gilead, Janssen, Bristol Myers Squibb, and Novartis. HH reports consulting for Bristol Myers Squibb, Sanofi, and Janssen. YE receives honoraria from Pfizer, GSK, Kite, Janssen, Sanofi, Bristol Myers Squibb, Orca, and Oncopeptides, and research funding via Pharmacyclics (Alliance) and GSK (Alliance). BD receives honoraria from Natera, GlaxoSmithKline, Menarini, Kite, and Janssen, consulting for Genentech, Caribou, Johnson & Johnson, Karyopharm, Bristol Myers Squibb, Janssen, Arcellx, and Pfizer, and research funding from Caribou, Ichnos, Kite, Carsgen, Bristol Myers Squibb, Janssen, Arcellx, and Pfizer. SU reports consulting or advisory roles with GSK, Takeda, SecuraBio, Amgen, Seagen, Johnson & Johnson/Janssen, Genentech, Sanofi, Gilead, Oncopeptides, Bristol Myers Squibb/Celgene, SkylineDX, AbbVie, EdoPharma, Gracell Therapeutics, TeneoBio, and AstraZeneca, and receives research funding from Janssen, Takeda, SecuraBio, Amgen, Seagen, Johnson & Johnson/Janssen, Sanofi, Gilead, Oncopeptides, Bristol Myers Squibb/Celgene, SkylineDX, AbbVie, EdoPharma, Gracell Therapeutics, and TeneoBio. OSA reports advisory board participation for Sanofi and Janssen, and consulting for Immix Biopharma. All remaining authors report no financial relationships relevant to this work.

Ethics approval: All Center for International Blood and Marrow Transplant Research studies are reviewed and approved by the National Marrow Donor Program Institutional Review Board, and all patients (or their legal guardians) provided informed consent for data collection and research.

Updates are available Correction dated 2026-08-31

Click to view Correction: https://doi.org/10.1038/s41408-026-01605-9